Recombinant factor VIIa: its background, development and clinical use
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Hematology
Reference20 articles.
1. Mechanism of action, development and clinical experience of recombinant FVIIa
2. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
3. The Continuing Risk of Transfusion-Transmitted Infections
4. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
5. Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Estudio de la actividad del inhibidor de la fibrinólisis activable por trombina (TAFI), en plasma de pacientes con generación de trombina disminuida;Investigación Clínica;2019-07-01
2. Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury;Journal of the Royal Army Medical Corps;2018-11-12
3. The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model;Frontiers in Cardiovascular Medicine;2018-06-12
4. Hematologic Problems in the Surgical Patient;Hematology;2018
5. The M358R variant of α 1 -proteinase inhibitor inhibits coagulation factor VIIa;Biochemical and Biophysical Research Communications;2016-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3